Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism.

IF 1.9 4区医学 Q3 PERIPHERAL VASCULAR DISEASE

International Journal of Hypertension Pub Date : 2023-01-01 DOI:10.1155/2023/6453933

Masanori Fujimoto, Suzuka Watanabe, Katsushi Igarashi, Yutaro Ruike, Kazuki Ishiwata, Kumiko Naito, Akiko Ishida, Masaya Koshizaka, Sawako Suzuki, Yuki Shiko, Hisashi Koide, Koutaro Yokote

{"title":"Antihypertensive Effects of Esaxerenone in Older Patients with Primary Aldosteronism.","authors":"Masanori Fujimoto, Suzuka Watanabe, Katsushi Igarashi, Yutaro Ruike, Kazuki Ishiwata, Kumiko Naito, Akiko Ishida, Masaya Koshizaka, Sawako Suzuki, Yuki Shiko, Hisashi Koide, Koutaro Yokote","doi":"10.1155/2023/6453933","DOIUrl":null,"url":null,"abstract":"Design: Retrospective cohort study. Patients. The data was obtained from a total of 87 PA patients treated with esaxerenone. The treatment group comprised 33 patients who received esaxerenone as first-line therapy and 54 patients that switched from another MRA to esaxerenone. Measurements. Blood pressure (BP), plasma aldosterone concentration (PAC), plasma renin activity (PRA), serum potassium level, estimated glomerular filtration rate (eGFR), urinary albumin-creatinine ratio (UACR), and brain natriuretic peptide (BNP) were assessed before and after treatment with esaxerenone. Patients with overall reductions in their systolic or diastolic BP by 10 mmHg, or more, were considered responders. Unpaired t-tests of the biochemical and personal parameters between responders and nonresponders were run to find the most influencing characteristic for treatment success.Results: BP overall decreased after treatment with esaxerenone (systolic BP: P=0.025, diastolic BP: P=0.096). Serum potassium levels increased, while eGFR decreased (P=0.047 and 0.043, respectively). No patients needed a dose reduction or treatment discontinuation of esaxerenone based on the serum potassium and eGFR criteria. UACR and BNP decreased insignificantly. The responders were significantly older than the nonresponders of the esaxerenone treatment (P=0.0035).Conclusions: Esaxerenone was effective in older patients with primary aldosteronism.","PeriodicalId":14132,"journal":{"name":"International Journal of Hypertension","volume":"2023 ","pages":"6453933"},"PeriodicalIF":1.9000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9873463/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/6453933","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 1

Abstract

Design: Retrospective cohort study. Patients. The data was obtained from a total of 87 PA patients treated with esaxerenone. The treatment group comprised 33 patients who received esaxerenone as first-line therapy and 54 patients that switched from another MRA to esaxerenone. Measurements. Blood pressure (BP), plasma aldosterone concentration (PAC), plasma renin activity (PRA), serum potassium level, estimated glomerular filtration rate (eGFR), urinary albumin-creatinine ratio (UACR), and brain natriuretic peptide (BNP) were assessed before and after treatment with esaxerenone. Patients with overall reductions in their systolic or diastolic BP by 10 mmHg, or more, were considered responders. Unpaired t-tests of the biochemical and personal parameters between responders and nonresponders were run to find the most influencing characteristic for treatment success.

Results: BP overall decreased after treatment with esaxerenone (systolic BP: P=0.025, diastolic BP: P=0.096). Serum potassium levels increased, while eGFR decreased (P=0.047 and 0.043, respectively). No patients needed a dose reduction or treatment discontinuation of esaxerenone based on the serum potassium and eGFR criteria. UACR and BNP decreased insignificantly. The responders were significantly older than the nonresponders of the esaxerenone treatment (P=0.0035).

Conclusions: Esaxerenone was effective in older patients with primary aldosteronism.

Abstract Image

查看原文本刊更多论文

依沙塞隆对老年原发性醛固酮增多症患者的降压作用。

设计:回顾性队列研究。病人。数据来自总共87例接受艾塞酮治疗的PA患者。治疗组包括33名接受艾塞塞隆作为一线治疗的患者和54名从另一种MRA转向艾塞塞隆的患者。测量。观察艾塞普龙治疗前后血压(BP)、血浆醛固酮浓度(PAC)、血浆肾素活性(PRA)、血清钾水平、肾小球滤过率(eGFR)、尿白蛋白-肌酐比(UACR)、脑钠肽(BNP)的变化。收缩压或舒张压总体降低10mmhg以上的患者被认为有反应。对反应者和无反应者之间的生化和个人参数进行非配对t检验，以找到对治疗成功影响最大的特征。结果:艾塞维酮治疗后血压总体下降(收缩压:P=0.025，舒张压:P=0.096)。血清钾水平升高，eGFR降低(P分别为0.047和0.043)。根据血清钾和eGFR标准，没有患者需要减少剂量或停药。UACR和BNP均无明显下降。对艾塞酮治疗有反应的患者年龄明显大于无反应的患者(P=0.0035)。结论:依沙塞隆对老年原发性醛固酮增多症患者有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Hypertension Medicine-Internal Medicine

CiteScore

4.00

自引率

5.30%

发文量

期刊介绍： International Journal of Hypertension is a peer-reviewed, Open Access journal that provides a forum for clinicians and basic scientists interested in blood pressure regulation and pathophysiology, as well as treatment and prevention of hypertension. The journal publishes original research articles, review articles, and clinical studies on the etiology and risk factors of hypertension, with a special focus on vascular biology, epidemiology, pediatric hypertension, and hypertensive nephropathy.